EWTX
Edgewise Therapeutics Inc
NASDAQ: EWTX · HEALTHCARE · BIOTECHNOLOGY
$44.40
+3.50% today
Updated 2026-09-11
Market cap
$4.76B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.85
Dividend yield
—
52W range
$14 – $48
Volume
1.1M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
9.1
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$51.69
+16.42%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy8 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 9.06 — safe zone
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-43.54M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-15.40M | $-100.16M | $-133.81M | $-167.79M | $-57.33M |
| EPS | — | — | — | — | $-1.85 |
| Free cash flow | $-58.18M | $-97.69M | $-110.34M | $-144.07M | $-43.54M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Edgewise Therapeutics Inc trades at $44.40. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 9.06, it sits in the safe zone.
Frequently asked questions
What is Edgewise Therapeutics Inc's stock price?
Edgewise Therapeutics Inc (EWTX) trades at $44.40.
Is Edgewise Therapeutics Inc overvalued?
Edgewise Therapeutics Inc carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Edgewise Therapeutics Inc (EWTX)?
The 12-month analyst consensus target is $51.69, about 16.4% above the current $44.40. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Edgewise Therapeutics Inc's Altman Z-Score is 9.06, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-35.69%
Beta0.33
50D MA$42.24
200D MA$32.98
Shares out0.11B
Float0.07B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—